NKGen Biotech, Inc. (NKGN)
0.011
0.00 (0.00%)
USD |
OTCM |
Nov 06, 16:00
NKGen Biotech Max Drawdown (5Y) : 100.00% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 100.00% |
| September 30, 2026 | 100.00% |
| August 31, 2026 | 100.00% |
| July 31, 2026 | 100.00% |
| June 30, 2026 | 100.00% |
| May 31, 2026 | 100.00% |
| April 30, 2026 | 100.00% |
| March 31, 2026 | 100.00% |
| Date | Value |
|---|---|
| February 28, 2026 | 100.00% |
| January 31, 2026 | 100.00% |
| December 31, 2025 | 100.00% |
| November 30, 2025 | 100.00% |
| October 31, 2025 | 100.00% |
| September 30, 2025 | 99.11% |
| August 31, 2025 | 99.11% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Intellia Therapeutics, Inc. | 96.45% |
| C4 Therapeutics, Inc. | 97.82% |
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sangamo Therapeutics, Inc. | 99.68% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -84.38 |
| Beta (5Y) | 0.7614 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 1.99K% |
| Historical Sharpe Ratio (5Y) | -0.0393 |
| Historical Sortino (5Y) | -0.8018 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 69.96% |